The U.S. Food and Drug Administration has approved retifanlimab-dlwr (Zynyz) for the treatment of locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). This marks the first oral therapy approved for anal cancer, offering a new treatment option for patients. Nurses involved in oncology care should be aware of this development as it may influence treatment protocols and patient education. (Oncology Nursing News)
Top Nurse CE | May 15, 2025
